Transvaginal Ultrasound and Laparoscopy-guided Microwave Ablation for Uterine Myoma and Adenomyosis: Preliminary Results.

IF 2.1 Q3 OBSTETRICS & GYNECOLOGY
Gynecology and Minimally Invasive Therapy-GMIT Pub Date : 2026-05-19 eCollection Date: 2026-04-01 DOI:10.4103/gmit.GMIT-D-25-00003
Chieh-Yu Chang, Jian-Lin Yeh, Cherng-Jye Jeng, Zi-Xi Loo, Kun-Ling Lin, Cheng-Yu Long
{"title":"Transvaginal Ultrasound and Laparoscopy-guided Microwave Ablation for Uterine Myoma and Adenomyosis: Preliminary Results.","authors":"Chieh-Yu Chang, Jian-Lin Yeh, Cherng-Jye Jeng, Zi-Xi Loo, Kun-Ling Lin, Cheng-Yu Long","doi":"10.4103/gmit.GMIT-D-25-00003","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The objective of the study was to evaluate the effectiveness of microwave ablation (MWA) in treating uterine myoma and adenomyosis.</p><p><strong>Materials and methods: </strong>Twenty premenopausal women aged 30-45 years, diagnosed with symptomatic uterine fibroids (<i>n</i> = 13) or adenomyosis (<i>n</i> = 7), were prospectively enrolled between November 2021 and March 2022 at Kaohsiung Medical University Hospital. All participants underwent percutaneous MWA under combined transvaginal ultrasound and laparoscopic guidance using a 13-gauge antenna and the Emprint™ Ablation Generator with Thermosphere™ technology. Contrast-enhanced MRI was used to assess lesion volume at baseline and 3 months postprocedure. Symptom severity and quality of life (QOL) were evaluated using the Visual Analogue Scale (VAS) for pain, Pictorial Blood Assessment Chart (PBAC) for menstrual bleeding, and the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire at baseline and at 1, 3, and 6 months posttreatment.</p><p><strong>Results: </strong>Follow-up showed significant reductions in pain, bleeding, and symptom severity. VAS, PBAC, and UFS-QOL scores all improved significantly. Myoma volume decreased by 33.4%, whereas adenomyosis showed meaningful symptom improvement despite nonsignificant volume change. No major complications occurred.</p><p><strong>Conclusion: </strong>Transvaginal ultrasound- and laparoscopy-guided MWA is a safe, effective, and minimally invasive treatment for uterine fibroids and adenomyosis, providing rapid symptom relief and improved QOL with uterine preservation.</p>","PeriodicalId":45272,"journal":{"name":"Gynecology and Minimally Invasive Therapy-GMIT","volume":"15 2","pages":"139-144"},"PeriodicalIF":2.1000,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13299103/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecology and Minimally Invasive Therapy-GMIT","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/gmit.GMIT-D-25-00003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The objective of the study was to evaluate the effectiveness of microwave ablation (MWA) in treating uterine myoma and adenomyosis.

Materials and methods: Twenty premenopausal women aged 30-45 years, diagnosed with symptomatic uterine fibroids (n = 13) or adenomyosis (n = 7), were prospectively enrolled between November 2021 and March 2022 at Kaohsiung Medical University Hospital. All participants underwent percutaneous MWA under combined transvaginal ultrasound and laparoscopic guidance using a 13-gauge antenna and the Emprint™ Ablation Generator with Thermosphere™ technology. Contrast-enhanced MRI was used to assess lesion volume at baseline and 3 months postprocedure. Symptom severity and quality of life (QOL) were evaluated using the Visual Analogue Scale (VAS) for pain, Pictorial Blood Assessment Chart (PBAC) for menstrual bleeding, and the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire at baseline and at 1, 3, and 6 months posttreatment.

Results: Follow-up showed significant reductions in pain, bleeding, and symptom severity. VAS, PBAC, and UFS-QOL scores all improved significantly. Myoma volume decreased by 33.4%, whereas adenomyosis showed meaningful symptom improvement despite nonsignificant volume change. No major complications occurred.

Conclusion: Transvaginal ultrasound- and laparoscopy-guided MWA is a safe, effective, and minimally invasive treatment for uterine fibroids and adenomyosis, providing rapid symptom relief and improved QOL with uterine preservation.

经阴道超声和腹腔镜引导下微波消融治疗子宫肌瘤和子宫腺肌症的初步结果。
目的:评价微波消融(MWA)治疗子宫肌瘤和子宫腺肌症的疗效。材料与方法:前瞻性研究于2021年11月至2022年3月在高雄医科大学附属医院招募20名年龄在30-45岁、诊断为症状性子宫肌瘤(n = 13)或子宫腺肌症(n = 7)的绝经前妇女。所有参与者在经阴道超声和腹腔镜联合引导下,使用13号天线和采用Thermosphere™技术的Emprint™消融发生器进行经皮MWA。对比增强MRI在基线和术后3个月评估病变体积。分别在基线及治疗后1、3、6个月采用视觉模拟评分法(VAS)评估疼痛的症状严重程度和生活质量(QOL),月经出血的血液图像评估表(PBAC)和子宫肌瘤症状和生活质量(UFS-QOL)问卷进行评估。结果:随访显示疼痛、出血和症状严重程度明显减轻。VAS、PBAC、UFS-QOL评分均有显著改善。肌瘤体积减少33.4%,而子宫腺肌症尽管体积变化不显著,但症状有明显改善。无重大并发症发生。结论:经阴道超声和腹腔镜引导下子宫肌瘤切除术是一种安全、有效、微创的治疗子宫肌瘤和子宫腺肌症的方法,可快速缓解症状,改善生活质量,并保留子宫。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
16.70%
发文量
98
审稿时长
52 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书